John Harris, MD, PhD, Chair of Dermatology at UMass Chan Medical School, discusses the impact topical ruxolitinib cream has had on patients with vitiligo. He explains how this treatment has shown exceptional efficacy with limited side effects.

Dr. Desai discusses the efficacy and longevity of treatment with ruxolitinib cream 1.5% in patients with facial vitiligo based on a recent post-hoc analysis of...
PLAY